Upload
letruc
View
241
Download
1
Embed Size (px)
Citation preview
[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 1 of 26
Guidance
producer:
British National Formulary
Publications
Guidance
product:
British National Formulary, British
National Formulary for Children
Date: 21 November 2016
Version: 1.3
Final Accreditation Report
[[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 2 of 26
Contents
Introduction ..................................................................................................................... 3
Accreditation recommendation ........................................................................................ 3
Background to the guidance producer............................................................................. 3
Summary…………………………………………………………………………………………4
Implementation ................................................................................................................ 7
Appendix A: NICE Accreditation analysis ........................................................................ 8
Appendix B: Bibliography .............................................................................................. 23
Appendix C: NICE Accreditation Advisory Committee, external advisers and NICE
Accreditation team......................................................................................................... 25
[[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 3 of 26
Introduction
The NICE Accreditation Programme recognises organisations that demonstrate high
standards in producing health or social care guidance. Users of the accredited guidance
can therefore have high confidence in the quality of the information. Organisations may
publicly display a seal of approval called an Accreditation Mark for 5 years after their
processes have been accredited. The process for accrediting producers of guidance
and recommendations for practice is described in the process manual.
Accreditation recommendation
NICE has accredited the process used by British National Formulary Publications
to produce British National Formulary and British National Formulary for
Children. Accreditation is valid for 5 years from 13 September 2016 and is
retrospectively applicable to guidance produced using Appendices 1 – 28 of the
process to develop BNF.
Background to the guidance producer
The BNF is a joint publication of the British Medical Association and the Royal
Pharmaceutical Society. It is published under the authority of a Joint Formulary
Committee which comprises representatives of the two professional bodies, the UK
Health Departments, the Medicines and Healthcare products Regulatory Agency
(MHRA), and a national guideline producer. The Dental Advisory Group (DAG)
oversees the preparation of advice in the BNF on the drug management of dental and
oral conditions; the group includes representatives of the British Dental Association and
a representative from the UK Health Departments.
The BNF for Children (BNFC) is a joint publication of the British Medical Association,
the Royal Pharmaceutical Society, the Royal College of Paediatrics and Child Health,
and the Neonatal and Paediatric Pharmacists Group. BNFC is published under the
authority of a Paediatric Formulary Committee which comprises representatives of
[[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 4 of 26
these bodies, the Department of Health for England, and the Medicines and Healthcare
products Regulatory Agency.
The majority of printed copies are sold to the National Institute for Health and Clinical
Excellence for distribution within the NHS in England and to the Departments of Health
for distribution within the NHS in Northern Ireland, Scotland, and Wales. The publishers
also sell the publication in both printed and electronic formats in the UK and the rest of
the world.
The Nurse Prescribers Formulary for Community Practitioners (NPF) is designed for
use with the BNF and BNFC; preparation of NPF content is overseen by the Nurse
Prescribers' Advisory Group (NPAG). The NPAG advises on the content relevant to
nurses and includes representatives from different parts of the nursing community and
from the UK Health Departments. The NPAG also advises UK health ministers on the
list of preparations that may be prescribed by Community Practitioner nurse prescribers.
Developed and evolved over a number of years since 1980 in response to changing
deliverables (e.g. the advent of electronic products) and the changing face of medical
information; during 2014–2015 there was a wide-ranging restructuring and process
improvement project in BNF Publications, which has led to BNF Publications being
reformatted to allow a wider digital strategy to be pursued. A number of key content
creation processes have consequently been updated and implemented during 2016; it is
these processes that form the basis of this application.
The last edition of the NPF was produced in 2015 and is published every 2 years. As
NPF content has not yet been updated using the new 2016 BNF processes there is
currently no evidence of implementation. The NPF is derived from the content of the
BNF and BNFC and uses the same identical process in its creation. Evidence of
implementation from monographs will be available in 2017 when the next edition of the
NPF is produced.
[[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 5 of 26
Summary
The Accreditation Advisory Committee considered that the processes used by British
National Formulary Publications to produce the British National Formulary and British
National Formulary for Children demonstrated compliance with 24 of the 25 criteria for
accreditation.
The scope and purpose of the publications are clear. The overall objectives, questions
addressed, intended users and target population are all clearly stated within both the
printed and online versions. The specific clinical circumstances in each monograph or
treatment summary is clear with links to the supporting evidence.
The process includes relevant multidisciplinary professionals throughout the
development process and lay representatives are included on the Joint Formulary and
Paediatric Formulary Committees. Consultation allows stakeholders, users and lay
representatives to comment.
There are clear documented processes for performing searches of a range of
databases and guidelines. Clear inclusion and exclusion criteria are applied and all
relevant evidence is assessed using a range of templates to ascertain the strength of
the evidence and recommendations and this is clearly presented in the content. Health
benefits, side effects and risks are considered and external peer review is undertaken
although the processes describing how primary guideline recommendations are
reworded is not currently documented. Recommendations are agreed by consensus or
voting if consensus cannot be achieved. All content is updated on a 3-4 year cycle with
processes in place to enable updates in response to new evidence.
The guidance provides clear recommendations and options for treatment or
management where appropriate. The dates of publication and the proposed date for
review are clearly stated in the guidance. The content and format of the guidance is
suitable for the specified target audience.
The BNF and BNFC are available in a range of formats to enable ease of use.
Organisational and financial barriers have been considered and included where
[[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 6 of 26
appropriate within the content. Monitoring of website usage and market research is
performed.
The funding source is clear and transparent to users. Editorial independence is
maintained. A documented policy is available for declaring and managing interests and
applies to all individuals involved in development.
A recommendation to improve the process used to produce British National Formulary
Publications is:
Documentation of the process for rewording and review of recommendations
derived from other sources, for example guidelines.
Professor Martin Underwood
Chair, Accreditation Advisory Committee
November 2016
[[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 7 of 26
Implementation
Following accreditation, guidance from the accredited producer will be identified on
NICE Evidence Search by the Accreditation Mark. The accredited guidance producer is
also granted a royalty-free, worldwide licence to use the NICE Accreditation Mark in
accordance with the Conditions and Terms of Use. Providing these conditions are met,
a guidance producer's accreditation will last for 5 years from the date of the
accreditation decision.
Accredited guidance producers must take reasonable steps to ensure the accredited
processes are followed when generating the type of evidence for which they are
accredited. Accredited guidance producers should have quality assurance mechanisms
in place and must inform NICE accreditation within 30 days if any significant change is
made to a process.
Figure 1: The NICE Accreditation Mark
[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 8 of 26
Appendix A: NICE Accreditation analysis
The Accreditation Advisory Committee considered the following analysis of the guidance producer’s compliance with NICE
Accreditation criteria, which covers 6 discrete domains. The full analysis leading to the accreditation decision is shown
below.
Criterion Evidence for meeting the criterion Accreditation
decision
Scope and
purpose
Does the guidance producer have a policy in place and adhered to that requires them to explicitly detail:
1.1 Overall objective BNF Publications have the same stated overall aim - to provide
prescribers, pharmacists and other healthcare professionals with up to
date information about the use of medicines. This objective is described in
the Preface to BNF Publications1, and summarised on the back cover of
print editions of BNF Publications2. The objectives are also contained
within the ‘About the BNF’ and ‘About the BNFC’ pages of the online
editions3.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 9 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
1.2 The clinical, healthcare or social questions covered
The publications address questions of drug safety, dosage, effectiveness
and adverse effects via clear medicines information. This is facilitated by
clinical information on conditions and classes of medicines to answer
questions around management of conditions and the appropriateness of
prescribing different types of medicines. The content creation policy4
contains a description of using PICO to develop focussed questions and
the document ‘How to use BNF Publications’5 describes the questions and
content within different standard sections of the monographs. There are
examples of ‘use cases for BNF Publications’6 which show how different
clinical scenarios and questions can be answered using the monographs.
Criterion met
1.3 Population and/or target audience to whom the guidance applies
The target audiences for all publications are detailed in the preface1, on
the rear covers2 and on the online versions of the BNF and BNFC3. The
populations covered by the BNF and BNFC are broad (adults and
children). Specific populations are defined in the entries for individual
drugs or drug class5,7,8.
Criterion met
1.4 Guidance includes clear recommendations in reference to specific clinical, healthcare or social circumstances
The clinical settings in which a medicine is recommended or not are
defined through information included as standard on indications,
contraindications and cautions, with extra clinical information provided for
some conditions and classes of medicines5,7,8.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 10 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
Stakeholder
involvement
Does the guidance producer have a policy in place and adhered to that means it includes:
2.1 Individuals from all relevant stakeholder groups, including patient groups, in developing guidance
All committees have a chairperson and are comprised of multidisciplinary
committee members and lay representatives. On the Joint Formulary
Committee (JFC) and Paediatric Formulary Committee (PFC) each
professional group is represented by between 2 and 4 individuals. Two lay
members were therefore thought to provide an appropriate balance to the
make-up of the committee as a whole. When required members with
backgrounds from nursing, medicine, paediatrics, pharmacy,
representatives of NICE, the Department of Health, and MHRA are
recruited9,10. The names, job roles and contact details of the 2015-16
membership are available showing the membership of stakeholder and
patient groups11.
Criterion met
2.2 Patient and service user representatives and seeks patient views and preferences in developing guidance
Patients and service users are recruited as members of both the JFC and
PFC9,10. They are also able to comment during the external peer review
stages as part of the public consultation. The 2015-2016 membership of
the committees confirms that lay members are included on both the JFC
and PFC11. Lay members receive an induction document12 that explains
their role within the committee and other supporting information to enable
them to perform the same functions as the rest of the committee
members.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 11 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
2.3 Representative intended
users in developing
guidance.
It is clear that target users of the BNF publications (health professionals
involved with prescribing, monitoring, supplying and administering drugs)
are representative of the membership of the JFC and PFC9. They are also
able to contribute as part of the peer review process. Evidence that target
users are representative of those developing guidance is apparent
because the occupational titles and qualifications, listed in the
membership11, of the target users and committees are very similar.
Criterion met
Rigour of
development
Does the guidance producer have a clear policy in place that:
3.1 Requires the guidance
producer to use
systematic methods to
search for evidence and
provide details of the
search strategy
The process9,13,14,15 for searching, selecting, and assessing evidence, as
well as the various search strategies, including filters to apply, search
terms used, and references identified are detailed within a range of
appendices and an example search16 showing the use of these processes
was provided. If relevant NICE or SIGN guidelines are identified and fully
answer the clinical question, a limited literature search can be carried out
to identify any further key evidence published since the guideline was
produced or updated. If the search does not identify any relevant NICE or
SIGN guidance, and/or the clinical question is not fully answered, a
complete literature search is performed and includes other high quality
clinical guidelines and primary literature.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 12 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
3.2 Requires the guidance
producers to state the
criteria and reasons for
inclusion or exclusion of
evidence identified by the
evidence review
The literature search procedure13 details any exclusions that are used in
the searches for evidence or guidelines. All relevant evidence or
guidelines that are identified during the searches undergo assessment
against defined criteria. The literature search and assessment of the
retrieved literature is completed by a single clinical writer. A second
clinical writer then independently evaluates the search strategy employed
and that assessment of the literature is correct. The example search16
shows the filters that were applied to the databases searched, the studies
considered for inclusion and the reasons for exclusion of any studies or
guidelines.
Criterion met
3.3 Describes the strengths
and limitations of the
body of evidence and
acknowledges any areas
of uncertainty
The process18 requires a range of different tools to be used to assess the
different types of evidence used in the development of BNF publications.
For each type of evidence there is a standard template18 which is used to
assess the validity and quality of the source. Guidance notes18 are
available for each template to reduce variability between reviewers. The
example16 shows the use of both the AGREE tool to assess a non-NICE
accredited guideline and checklist to assess a meta-analysis study.
The SIGN grading system9,17 is used to assign a level of evidence (1++
through 4) and grade of recommendation (A through E). The grade of
recommendation is clearly indicated in the example18.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 13 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
3.4 Describes the method
used to arrive at
recommendations (for
example, a voting system
or formal consensus
techniques like Delphi
consensus)
The Standing Orders of the committees of BNF Publications10 states that
consensus is the method of choice to set recommendations. When
consensus cannot be reached the Chair of the committee will indicate that
a vote is required. The votes for and against the amendment are
recorded in the minutes. Committee members reserve the right to abstain
and the side with the majority of votes will win. In instances where there
are equal numbers of votes the Chair has the casting (deciding) vote.
Minutes supplied from a combined meeting of the Paediatric and Joint
Formulary Committees19 confirm that voting was used to help decide to
provide a link to a NICE guideline to help with diagnosis.
Criterion met
3.5 Requires the guidance
producers to consider the
health benefits against
the side effects and risks
in formulating
recommendations
It is a fundamental objective of the BNF publications to consider and state
health benefits, side effects and risks. The Monograph control sheet14
requires the authors to tick off each section as it has been considered for
inclusion. These sections include side-effects, safety considerations,
contraindications and cautions. Consideration is also required for these
different sections in special patient populations including pregnancy and
renal insufficiency. The content creation policy4 instructs authors to
consider several factors including the impact of treatment and symptom
management. The example monographs7 and summaries clearly show
sections considering the side effects, health benefits and risks.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 14 of 26
3.6 Describes the processes
of external peer review
The process19,20 for peer review of recommendations requires content
containing recommendations to be passed to the JFC and/or PFC for a
first validation step. Following this if the recommendation is not directly
derived from guidelines, the evidence base is of insufficient quality to
allow a moderate or high strength grade of recommendation or there was
significant debate at the committee stage then the recommendations are
sent for further external peer review either by open or restricted
consultation depending on the content. Potential stakeholders or special
interest groups are notified, the BNF website is updated with information
of the consultation and notification is included in the BNF e Newsletter.
Responses are collated by the BNF publications team for review and any
actions documented and changes made if required as seen in the
example supplied18.
When content from high quality sources for example NICE or SIGN
guidelines is used to develop recommendations, the original
recommendations may be reworded when incorporated within the BNF
publication. The rewording is performed by two independent pharmacists
and checked by a third. The content is then presented to the JFC or PFC
for review to ensure the rewording accurately represents the meaning of
the primary guideline. These recommendations do not usually then go for
further peer review. This process is currently not explicitly documented
within the process so it may be unclear to users how these
recommendations are developed.
Not fully met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 15 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
3.7 Describes the process of
updating guidance and
maintaining and
improving guidance
quality
Development and maintenance of BNF Publications9,21 is both proactive
where there are aims to revalidate all content over a rolling 3- to 4-year
period or reactive and designed to address significant changes to the
body of medical evidence, such as a Drug Safety Alert or the licensing of
a new drug. Print editions of the BNF are released every 6 months and
new editions of the BNFC every year; while online they are updated each
month. Medicines information is reviewed every 3 years or sooner if new
evidence becomes available.
The BNF and BNFC state how often they are updated online and in hard
copy versions. Important changes since the last edition are clearly stated
in the publications. Monographs state the date of last update7.
Criterion met
Clarity and
presentation
Does the guidance producer ensure that:
4.1 Recommendations are
specific, unambiguous
and clearly identifiable
The layout of information in each monograph and treatment summary
follows a standardised structure as described by a number of process
documents4,9,22 that explain how medicines information including product
characteristics, warnings and side effects should be presented across the
different BNF products. Example monographs7 show that
recommendations are clear, unambiguous and easily identifiable, and in a
standard format.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 16 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
4.2 Different options for the
management of the
condition or options for
intervention are clearly
presented
The content creation process4 guides the writers to consider both drug
and non-drug options for management. Example treatment summaries for
diverticular disease16 and Irritable bowel syndrome18 show different
options including non-drug interventions if appropriate.
Criterion met
4.3 The date of search, the
date of publication or last
update and the proposed
date for review are clearly
stated
The month and year of publication along with the timeframe for review of
the BNF and BNFC printed publications are shown on the cover2. The
online versions3,22 of the BNF Publications provide the month and year of
the current version and offer monthly updates as specified on the website.
Monographs and treatment summaries published from 2016 are each
individually dated with the date of last update7,16.
Although the search dates are not provided explicitly the updating
frequency for each publication is clearly stated in the process
documentation9 and in the publications. This allows users to be aware of
the timeliness of any new evidence assimilated into the latest edition
(monthly for the BNF and BNFC online, 6 months for the BNF in print, 1
year for the BNFC). As content is based on regular scanning of key
sources rather than one-off searches this is considered appropriate for
this type of guidance producer.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 17 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
4.4 The content of the
guidance is suitable for
the specified target
audience. If patients or
service users are part of
this audience, the
language should be
appropriate.
The processes4,9 ensure the layout of information in each monograph and
treatment summary follows a standardised structure. The BNF
publications style guide22 ensures the language used in content is
consistent. Example monographs7 show that the language is technical in
nature but is appropriate for the target audiences. The wording of the
cautionary and advisory warnings for patients appears clear and is jargon
free24.
Criterion met
Applicability Does the guidance producer routinely consider:
5.1 Publishing support tools
to aid implementation of
guidance
The BNF Publications can be considered as concise reference tools which
assist clinicians to implement the recommendations. Online versions of
the BNF Publications are available to subscribers which contain recent
updates and provide a fast way to find medicines information. The BNF is
also available for smart-phones. Any changes, including content changes
are highlighted for quick reference both in monthly newsletters25 and
within the front pages1 of the BNF printed versions to aid users.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 18 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
5.2 Discussion of potential
organisational and
financial barriers in
applying its
recommendations
The BNF Publications section entitled ‘Taking medicines to best effect’
provides advice for clinicians in overcoming barriers when implementing a
medicines treatment plan. The price of a medicine would only influence
the development of recommendations when cost effectiveness had been
assessed. It is beyond the remit of the BNF products to assess the cost
effectiveness of medicines. However, the results of NICE appraisals and
SIGN reviews are provided where available7.
Criterion met
5.3 Review criteria for
monitoring and/or audit
purposes within each
product.
Usage of the BNF is monitored through a range of market research
activities26. Google analytics are used to monitor website usage and is
helpful for determining trends and patterns of usage of BNF Publications
online26.
Criterion met
Does the guidance producer:
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 19 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
Editorial
independence
6.1 Ensure editorial
independence from the
funding body
Standing Orders of the Formulary Committees of the British National
Formulary Publications10 states, the BNF is ‘independent of government
and industry’ and is a joint publication of the British Medical Association
(BMA) and Royal Pharmaceutical Society (RPS). The BNFC is a
collaborative publication of the BMA, RPS, Royal College of Paediatrics
and Child Health (RCPCH) and Neonatal and Paediatric Pharmacist
Group (NPPG) which are all organisations independent of the NHS. All
external advisers and committee members declare any conflicts of
interest. The NHS is the main funding source but it would not be possible
to guarantee adequate professional stakeholder involvement without
including a variety of NHS employees in the development of the BNF. In
practice, the NHS employees who sit on the committees are not
responsible for buying the BNF, so editorial independence is preserved.
Criterion met
6.2 Demonstrate
transparency about the
funding mechanisms for
its guidance
A statement on the BNF Publications website27 explains that the BNF is
entirely funded from sales made by the joint publishers, the BMJ Group
and Pharmaceutical Press. The majority of printed copies are sold to the
National Institute for Health and Clinical Excellence for distribution within
the NHS in England and to the Departments of Health for distribution
within the NHS in Northern Ireland, Scotland, and Wales. The publishers
also sell the publication in both printed and electronic formats in the UK
and the rest of the world.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 20 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
6.3 Record and state any
potential conflicts of
interest of individuals
involved in developing
the recommendations
The Standing orders of the formulary committees10 and the Monitoring and
managing conflicts of interest policy28 provide detailed requirements for all
individuals, including committee members, editorial staff and peer
reviewers, involved in development to declare interests. The interests that
need to be declared and how they are managed is described within the
policy. The policies are freely available and the declarations made are
available upon request.
Criterion met
6.4 Take account of any
potential for bias in the
conclusions or
recommendations of the
guidance
The process ensures that development of BNF publications is systematic
and includes a range of multidisciplinary professionals and lay
representatives. It is clear how recommendations are reached. All
individuals involved in development including peer reviewers must declare
any interests and there is a clear process for managing any interests.
Criterion met
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 21 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
Documents referenced above:
1 Appendix 1 – Front Matter
2 Appendix 2 – Book covers
3 Online version of BNF & BNFC
4 Appendix 23 - BNF content creation policies
5 Appendix 3 - How to use BNF Publications
6 Appendix 4 - Use cases for BNF Publications
7 Appendix 5 - Monographs
8 Appendix 6 - Guidance sections
9 Appendix 8 - How BNF Publications are constructed
10 Appendix 9 - Standing Orders of the Formulary Committees of BNF Publications
11 Appendix 10 -BNF Committees - members, disciplines and affiliations
12 Appendix 12 - Lay member support documentation
13 Appendix 14 - Literature search procedure for content creation
14 Appendix 15 - Monograph control sheet
15 Appendix 16 - Evidence table for Literature search
16 Appendix 17 -Development of the diverticular disease and diverticulitis treatment summary
[[British National Formulary Publications:British National Formulary, British National Formulary for Children]: Final Accreditation Report
Page 22 of 26
Criterion Evidence for meeting the criterion Accreditation
decision
17 Appendix 18 -Evidence assessment documentation
18 Appendix 7 - Development of the Irritable bowel syndrome treatment summary
17 Appendix 20 - Minutes from the combined meeting of the Paediatric and Joint Formulary Committees 4.11.15
18 Appendix 21- Peer review proforma
19 Appendix 19 -BNF Standard Operating Procedures
20 Appendix 22 - BNF Publications style
21 Appendix 24 - BNF homepage on MedicinesComplete
22 Appendix 11 - Cautionary and advisory labels
23 Appendix 25 -BNF February newsletter
24 Appendix 26 -Monitoring and analysis
25 BNF Publications website
26 Appendix 27 -Monitoring and managing conflicts of interest
[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 23 of 26
Appendix B: Bibliography
Appendix B lists the additional information taken into account in the analysis and
considered by the committee.
Document name Description Location
Appendix 1 - Front matter Process documentation Supplied Appendix 2 - Book covers Process documentation Supplied Appendix 3 - How to use BNF Publications
Process documentation Supplied
Appendix 4 - Use cases for BNF Publications
Process documentation Supplied
Appendix 5 - Monographs Implementation evidence Supplied Appendix 6 - Guidance sections
Process documentation Supplied
Appendix 7 - Development of the Irritable bowel syndrome treatment summary
Process documentation Supplied
Appendix 8 - How BNF Publications are constructed
Process documentation Supplied
Appendix 9 - Standing Orders of the Formulary Committees of BNF Publications
Process documentation Supplied
Appendix 10 - BNF Committees - members, disciplines and affiliations
Process documentation Supplied
Appendix 11 - Cautionary and advisory labels
Process documentation Supplied
Appendix 12 - Lay member support documentation
Process documentation Supplied
Appendix 13 - Content creation flowchart
Process documentation Supplied
Appendix 14 - Literature search procedure for content creation
Process documentation Supplied
Appendix 15 - Monograph control sheet
Process documentation Supplied
Appendix 16 - Evidence table for Literature search
Process documentation Supplied
[[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 24 of 26
Document name Description Location
Appendix 17 -Development of the diverticular disease and diverticulitis treatment summary
Process documentation Supplied
Appendix 18 - Evidence assessment documentation
Process documentation Supplied
Appendix 19 - BNF Standard Operating Procedures
Process documentation Supplied
Appendix 20 - Minutes from the combined meeting of the Paediatric and Joint Formulary Committees 4.11.15
Process documentation Supplied
Appendix 21- Peer review proforma
Process documentation Supplied
Appendix 22 - BNF Publications style
Process documentation Supplied
Appendix 23 - BNF content creation policies
Process documentation Supplied
Appendix 24 - BNF homepage on MedicinesComplete
Process documentation Supplied
Appendix 25 - BNF February newsletter
Process documentation Supplied
Appendix 26 - Monitoring and analysis
Process documentation Supplied
Appendix 27 - Monitoring and managing conflicts of interest
Process documentation Supplied
Appendix 28 - Training tools
Process documentation Supplied
[[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 25 of 26
Appendix C: NICE Accreditation Advisory Committee,
external advisers and NICE Accreditation team
NICE Accreditation Advisory Committee
The NICE Accreditation Advisory Committee operates as a standing advisory committee
of the Board of the National Institute for Health and Care Excellence (NICE). The
Committee provides advice to NICE on a framework for accrediting sources of evidence
that should be recognised as trusted sources of information for the NHS. The Chair of the
Committee is appointed by the NICE Board and the meetings are conducted by the chair
or in his/her absence the vice chair. The current Chair is Martin Underwood. A full list of
the Accreditation Advisory Committee membership is available on the NICE website.
Members are appointed for a period of 3 years. This may be extended by mutual
agreement for a further 3 years, up to a maximum term of office of 10 years.
The decisions of the Committee are arrived at by a consensus of the members present.
The quorum is set at 50% of committee membership. The Committee submits its
recommendations to the NICE Publication Executive which acts under delegated
powers of the NICE Board in considering and approving its recommendations.
Committee members are asked to declare any interests in the guidance producer to be
accredited. If it is considered that there is a conflict of interest, the member(s) is
excluded from participating further in the discussions. Committee members who took
part in the discussions for this accreditation decision are listed below.
Title Name Surname Role Organisation
Ms Judy Birch Lay Member N/A
Dr Adrian Brown Principal Screening Advisor, Public Health
Mr Richard Brownhill Self employed - Independent health care improvement manager
Royal Bolton Hospitals Trust
Mrs Lynda Cox Knowledge and Information Lead
NHS England
[[British National Formulary Publications:British National Formulary, British National Formulary for
Children]: Final Accreditation Report
Page 26 of 26
Ms Joyce Epstein Lay Member N/A
Dr Elvira Garcia Consultant in Public Health Medicine - Health Protection Lead
NHS Ayrshire & Arran
Ms Barbara Graham Information Consultant/Senior Health Economist
Public Health Intelligence, NHS National Services Scotland
Dr Steve Hajioff Director of Public Health Hillingdon Borough Council
Dr Anthony Larkin General Practitioner The Alexandra Practice
Ms Mandy Sainty Research and Development Manager
College of Occupational Therapists
Mr Duncan Service Evidence Manager SIGN
Dr Sara Twaddle Director of Evidence Healthcare Improvement Scotland
Prof. Martin Underwood
Professor of Primary Care Research, Director of Warwick Clinical Trials Unit
The University of Warwick
External Advisers for this accreditation application
Dr Andrea Hilton, Lecturer and practising pharmacist, University of Hull, UK
Professor António Vaz Carneiro, Head of the Centre for Evidence Based Medicine,
Director of Cochrane Portugal, Lisbon, Portugal
NICE Accreditation team for this accreditation application
John Huston, Accreditation Technical Analyst, National Institute for Health and Care
Excellence, Manchester, UK
Victoria Carter, Senior Accreditation Technical Analyst, National Institute for Health and
Care Excellence, Manchester, UK
Deborah Collis, Associate Director, National Institute for Health and Care Excellence,
Manchester, UK